Norberto Perico

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3902616/publications.pdf

Version: 2024-02-01

		4641	326
298	126,502	85	287
papers	citations	h-index	g-index

310	310	310	139834
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, The, 2012, 380, 2095-2128.	6.3	11,038
2	Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1789-1858.	6.3	8,569
3	Global burden of 369 diseases and injuries in 204 countries and territories, 1990â€“2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, The, 2020, 396, 1204-1222.	6.3	7,664
4	Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990â€“2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, The, 2012, 380, 2197-2223.	6.3	7,061
5	Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990â€“2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, The, 2012, 380, 2163-2196.	6.3	6,376
6	Global, regional, and national ageâ€“sex specific all-cause and cause-specific mortality for 240 causes of death, 1990â€“2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2015, 385, 117-171.	6.3	5,847
7	Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1211-1259.	6.3	5,578
8	Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1545-1602.	6.3	5,298
9	Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1736-1788.	6.3	4,989
10	Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990â€“2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2015, 386, 743-800.	6.3	4,951
11	Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1459-1544.	6.3	4,934
12	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1659-1724.	6.3	4,203
13	Global burden of 87 risk factors in 204 countries and territories, 1990â€“2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, The, 2020, 396, 1223-1249.	6.3	3,928
14	Global, regional, and national age-sex specific mortality for 264 causes of death, 1980â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1151-1210.	6.3	3,565
15	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1923-1994.	6.3	3,269
16	Global, regional, and national burden of chronic kidney disease, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2020, 395, 709-733.	6.3	2,858
17	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990â€“2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2015, 386, 2287-2323.	6.3	2,184
18	Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1859-1922.	6.3	2,123

#	Article	IF	Citations
19	Global, regional, and national burden of stroke, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology, The, 2019, 18, 439-458.	4.9	2,005
20	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1345-1422.	6.3	1,879
21	Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1603-1658.	6.3	1,612
22	Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1260-1344.	6.3	1,589
23	Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990â€“2013: quantifying the epidemiological transition. Lancet, The, 2015, 386, 2145-2191.	6.3	1,544
24	Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet, The, 2012, 380, 2129-2143.	6.3	1,013
25	Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950â€“2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. Lancet, The, 2020, 396, 1160-1203.	6.3	890
26	Delayed graft function in kidney transplantation. Lancet, The, 2004, 364, 1814-1827.	6.3	828
27	Global, regional, and national levels of maternal mortality, 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1775-1812.	6.3	740
28	Global, regional, and national age-sex-specific mortality and life expectancy, 1950â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1684-1735.	6.3	716
29	Mesenchymal Stem Cells Are Renotropic, Helping to Repair the Kidney and Improve Function in Acute Renal Failure. Journal of the American Society of Nephrology: JASN, 2004, 15, 1794-1804.	3.0	690
30	Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. Lancet, The, 2018, 391, 2236-2271.	6.3	638
31	Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1084-1150.	6.3	573
32	Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1725-1774.	6.3	571
33	Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990â€“2015: a novel analysis from the Global Burden of Disease Study 2015. Lancet, The, 2017, 390, 231-266.	6.3	480
34	Global and National Burden of Diseases and Injuries Among Children and Adolescents Between 1990 and 2013. JAMA Pediatrics, 2016, 170, 267.	3.3	479
35	Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980â€“2015: the Global Burden of Disease Study 2015. Lancet HIV,the, 2016, 3, e361-e387.	2.1	461
36	Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1813-1850.	6.3	413

#	Article	IF	Citations
37	Pretransplant Infusion of Mesenchymal Stem Cells Prolongs the Survival of a Semiallogeneic Heart Transplant through the Generation of Regulatory T Cells. Journal of Immunology, 2008, 181, 3933-3946.	0.4	405
38	The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney International, 2005, 68, S57-S65.	2.6	381
39	Human Bone Marrow Mesenchymal Stem Cells Accelerate Recovery of Acute Renal Injury and Prolong Survival in Mice. Stem Cells, 2008, 26, 2075-2082.	1.4	351
40	Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): a cross-sectional study. The Lancet Global Health, 2016, 4, e307-e319.	2.9	350
41	Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 2091-2138.	6.3	335
42	Five insights from the Global Burden of Disease Study 2019. Lancet, The, 2020, 396, 1135-1159.	6.3	335
43	Child and Adolescent Health From 1990 to 2015. JAMA Pediatrics, 2017, 171, 573.	3.3	306
44	Population and fertility by age and sex for 195 countries and territories, 1950â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1995-2051.	6.3	294
45	Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1423-1459.	6.3	284
46	Autologous Mesenchymal Stromal Cells and Kidney Transplantation. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 412-422.	2.2	273
47	Mechanisms of Disease: pre-eclampsia. Nature Clinical Practice Nephrology, 2005, 1, 98-114.	2.0	259
48	Chronic Renal Diseases: Renoprotective Benefits of Reninâ€“Angiotensin System Inhibition. Annals of Internal Medicine, 2002, 136, 604.	2.0	235
49	Regulatory T Cells and T Cell Depletion: Role of Immunosuppressive Drugs. Journal of the American Society of Nephrology: JASN, 2007, 18, 1007-1018.	3.0	224
50	Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial. Lancet, The, 2013, 382, 1485-1495.	6.3	218
51	Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney International, 2002, 62, 1060-1067.	2.6	214
52	von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Blood, 2002, 100, 778-785.	0.6	200
53	Global Cardiovascular and Renal Outcomes of Reduced GFR. Journal of the American Society of Nephrology: JASN, 2017, 28, 2167-2179.	3.0	194
54	Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion. Kidney International, 1993, 43, 706-711.	2.6	189

#	Article	IF	Citations
55	Performance of Different Prediction Equations for Estimating Renal Function in Kidney Transplantation. American Journal of Transplantation, 2004, 4, 1826-1835.	2.6	184
56	Hepatitis C Infection and Chronic Renal Diseases. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 207-220.	2.2	184
57	Recellularization of Well-Preserved Acellular Kidney Scaffold Using Embryonic Stem Cells. Tissue Engineering - Part A, 2014, 20, 1486-1498.	1.6	169
58	Maintenance Dialysis throughout the World in Years 1990 and 2010. Journal of the American Society of Nephrology: JASN, 2015, 26, 2621-2633.	3.0	159
59	Sirolimus Therapy to Halt the Progression of ADPKD. Journal of the American Society of Nephrology: JASN, 2010, 21, 1031-1040.	3.0	157
60	Disparities in Chronic Kidney Disease Prevalence among Males and Females in 195 Countries: Analysis of the Global Burden of Disease 2016 Study. Nephron, 2018, 139, 313-318.	0.9	156
61	Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial. Lancet, The, 2004, 364, 503-512.	6.3	155
62	Renal endothelin gene expression is increased in remnant kidney and correlates with disease progression. Kidney International, 1993, 43, 354-358.	2.6	153
63	DAILY RENAL HYPOPERFUSION INDUCED BY CYCLOSPORINE IN PATIENTS WITH RENAL TRANSPLANTATION. Transplantation, 1992, 54, 56-60.	0.5	151
64	Localization of Mesenchymal Stromal Cells Dictates Their Immune or Proinflammatory Effects in Kidney Transplantation. American Journal of Transplantation, 2012, 12, 2373-2383.	2.6	151
65	Mesenchymal stromal cells and kidney transplantation: pretransplant infusion protects from graft dysfunction while fostering immunoregulation. Transplant International, 2013, 26, 867-878.	0.8	148
66	A Genome-Wide Association Study of Diabetic Kidney Disease in Subjects With Type 2 Diabetes. Diabetes, 2018, 67, 1414-1427.	0.3	136
67	THYMIC RECOGNITION OF CLASS II MAJOR HISTOCOMPATIBILITY COMPLEX ALLOPEPTIDES INDUCES DONOR-SPECIFIC UNRESPONSIVENESS TO RENAL ALLOGRAFTS. Transplantation, 1993, 56, 461-465.	0.5	133
68	Mesenchymal stromal cells in renal transplantation: opportunities and challenges. Nature Reviews Nephrology, 2016, 12, 241-253.	4.1	132
69	Kidney graft survival in rats without immunosuppressants after intrathymic glomerular transplantation. Lancet, The, 1991, 337, 750-752.	6.3	131
70	New therapeutics that antagonize endothelin: promises and frustrations. Nature Reviews Drug Discovery, 2002, 1, 986-1001.	21.5	130
71	Mapping child growth failure across low- and middle-income countries. Nature, 2020, 577, 231-234.	13.7	128
72	Bone Marrowâ€“Derived Mesenchymal Stem Cells Improve Islet Graft Function in Diabetic Rats. Transplantation Proceedings, 2009, 41, 1797-1800.	0.3	126

#	Article	IF	Citations
73	Multipotent Mesenchymal Stromal Cell Therapy and Risk of Malignancies. Stem Cell Reviews and Reports, 2013, 9, 65-79.	5.6	125
74	A developmental approach to the prevention of hypertension and kidney disease: a report from the Low Birth Weight and Nephron Number Working Group. Lancet, The, 2017, 390, 424-428.	6.3	125
75	MECHANISMS OF ACQUIRED THYMIC UNRESPONSIVENESS TO RENAL ALLOGRAFTS. Transplantation, 1994, 58, 125-132.	0.5	124
76	Kidney Injury Molecule 1: In Search of Biomarkers of Chronic Tubulointerstitial Damage and Disease Progression. American Journal of Kidney Diseases, 2009, 53, 1-4.	2.1	123
77	Role of Insulin and Atrial Natriuretic Peptide in Sodium Retention in Insulin-Treated IDDM Patients During Isotonic Volume Expansion. Diabetes, 1990, 39, 289-298.	0.3	118
78	Hemolytic Uremic Syndrome: A Fatal Outcome after Kidney and Liver Transplantation Performed to Correct Factor H Gene Mutation. American Journal of Transplantation, 2005, 5, 1146-1150.	2.6	116
79	The Impact of Kidney Development on the Life Course: A Consensus Document for Action. Nephron, 2017, 136, 3-49.	0.9	110
80	Role of endothelium-derived nitric oxide in the bleeding tendency of uremia.. Journal of Clinical Investigation, 1990, 86, 1768-1771.	3.9	110
81	Nature and extent of glomerular injury induced by cyclosporine in heart transplant patients. Kidney International, 1991, 40, 243-250.	2.6	105
82	The Aggravating Mechanisms of Aldosterone on Kidney Fibrosis. Journal of the American Society of Nephrology: JASN, 2008, 19, 1459-1462.	3.0	99
83	Antiproteinuric Therapy while Preventing the Abnormal Protein Traffic in Proximal Tubule Abrogates Protein- and Complement-Dependent Interstitial Inflammation in Experimental Renal Disease. Journal of the American Society of Nephrology: JASN, 1999, 10, 804-813.	3.0	99
84	Sirolimus Versus Cyclosporine Therapy Increases Circulating Regulatory T Cells, But Does Not Protect Renal Transplant Patients Given Alemtuzumab Induction From Chronic Allograft Injury. Transplantation, 2007, 84, 956-964.	0.5	94
85	Nature and mediators of renal lesions in kidney transplant patients given cyclosporine for more than one year. Kidney International, 1999, 55, 674-685.	2.6	93
86	Mapping geographical inequalities in access to drinking water and sanitation facilities in low-income and middle-income countries, 2000â€“17. The Lancet Global Health, 2020, 8, e1162-e1185.	2.9	91
87	C-440T/T-331C polymorphisms in theUGT1A9gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. Pharmacogenomics, 2007, 8, 1127-1141.	0.6	86
88	THE ACUTE EFFECT OF FK506 AND CYCLOSPORINE ON ENDOTHELIAL CELL FUNCTION AND RENAL VASCULAR RESISTANCE. Transplantation, 1992, 54, 775-779.	0.5	84
89	Tackling the Shortage of Donor Kidneys: How to Use the Best that We Have. American Journal of Nephrology, 2003, 23, 245-259.	1.4	81
90	Timed Urine Collections Are Not Needed to Measure Urine Protein Excretion in Clinical Practice. American Journal of Kidney Diseases, 2006, 47, 1-7.	2.1	81

#	Article	IF	Citations
91	Prevention of Transplant Rejection. Drugs, 1997, 54, 533-570.	4.9	80
92	Predicting Cisplatin-Induced Acute Kidney Injury by Urinary Neutrophil Gelatinase-Associated Lipocalin Excretion: A Pilot Prospective Case-Control Study. Nephron Clinical Practice, 2010, 115, c154-c160.	2.3	79
93	Present and future drug treatments for chronic kidney diseases: evolving targets in renoprotection. Nature Reviews Drug Discovery, 2008, 7, 936-953.	21.5	77
94	Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients. Clinical Transplantation, 2001, 15, 402-409.	0.8	75
95	In Kidney Transplant Patients, Alemtuzumab but Not Basiliximab/Low-Dose Rabbit Anti-Thymocyte Globulin Induces B Cell Depletion and Regeneration, Which Associates with a High Incidence of De Novo Donor-Specific Anti-HLA Antibody Development. Journal of Immunology, 2013, 191, 2818-2828.	0.4	75
96	Application of newer clearance techniques for the determination of glomerular filtration rate. Current Opinion in Nephrology and Hypertension, 1998, 7, 675-680.	1.0	74
97	Influence of Co-Medication with Sirolimus or Cyclosporine on Mycophenolic Acid Pharmacokinetics in Kidney Transplantation. American Journal of Transplantation, 2005, 5, 2937-2944.	2.6	72
98	Mapping geographical inequalities in childhood diarrhoeal morbidity and mortality in low-income and middle-income countries, 2000â€“17: analysis for the Global Burden of Disease Study 2017. Lancet, The, 2020, 395, 1779-1801.	6.3	72
99	Chronic kidney disease: a research and public health priority. Nephrology Dialysis Transplantation, 2012, 27, iii19-iii26.	0.4	71
100	Mesenchymal stromal cells to promote solid organ transplantation tolerance. Current Opinion in Organ Transplantation, 2013, 18, 51-58.	0.8	70
101	Increased urinary excretion of thromboxane B2 and 2,3-dinor-TxB2 in cyclosporin A nephrotoxicity. Kidney International, 1988, 34, 164-174.	2.6	69
102	Long-Term Renal Allograft Function on a Tacrolimus-Based, Pred-Free Maintenance Immunosuppression Comparing Sirolimus vs. MMF+.. American Journal of Transplantation, 2006, 6, 1617-1623.	2.6	68
103	Nephrotoxic aspects of cyclosporine. Transplantation Proceedings, 2004, 36, S234-S239.	0.3	67
104	Advancement of Mesenchymal Stem Cell Therapy in Solid Organ Transplantation (MISOT). Transplantation, 2010, 90, 124-126.	0.5	66
105	Toward MSC in Solid Organ Transplantation: 2008 Position Paper of the MISOT Study Group. Transplantation, 2009, 88, 614-619.	0.5	64
106	The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin.. Journal of the American Society of Nephrology: JASN, 1998, 9, 2308-2317.	3.0	64
107	ACE inhibition induces regression of proteinuria and halts progression of renal damage in a genetic model of progressive nephropathy. American Journal of Kidney Diseases, 1999, 34, 626-632.	2.1	62
108	Propionyl-l-carnitine prevents renal function deterioration due to ischemia/reperfusion. Kidney International, 2002, 61, 1064-1078.	2.6	61

#	Article	IF	Citations
109	ABCB1 Genotypes Predict Cyclosporine-Related Adverse Events and Kidney Allograft Outcome. Journal of the American Society of Nephrology: JASN, 2009, 20, 1404-1415.	3.0	60
110	Maternal and environmental risk factors for neonatal AKI and its long-term consequences. Nature Reviews Nephrology, 2018, 14, 688-703.	4.1	60
111	Glomerular hyperfiltration. Nature Reviews Nephrology, 2022, 18, 435-451.	4.1	60
112	Nature and Mediators of Parietal Epithelial Cell Activation in Glomerulonephritides of Human and Rat. American Journal of Pathology, 2013, 183, 1769-1778.	1.9	59
113	From Pharmacokinetics to Pharmacogenomics: A New Approach to Tailor Immunosuppressive Therapy. American Journal of Transplantation, 2004, 4, 299-310.	2.6	58
114	Burden of CKD, Proteinuria, and Cardiovascular Risk Among Chinese, Mongolian, and Nepalese Participants in the International Society of Nephrology Screening Programs. American Journal of Kidney Diseases, 2010, 56, 915-927.	2.1	58
115	Long-Term Clinical and Immunological Profile of Kidney Transplant Patients Given Mesenchymal Stromal Cell Immunotherapy. Frontiers in Immunology, 2018, 9, 1359.	2.2	58
116	Mapping disparities in education across low- and middle-income countries. Nature, 2020, 577, 235-238.	13.7	58
117	Blunted excretory response to atrial natriuretic peptide in experimental nephrosis. Kidney International, 1989, 36, 57-64.	2.6	57
118	Therapeutic Drug Monitoring of Sirolimus: Effect of Concomitant Immunosuppressive Therapy and Optimization of Drug Dosing. American Journal of Transplantation, 2004, 4, 1345-1351.	2.6	57
119	Whole-Blood Calcineurin Activity Is Not Predicted by Cyclosporine Blood Concentration in Renal Transplant Recipients. Clinical Chemistry, 2001, 47, 1679-1687.	1.5	56
120	V1/V2 Vasopressin receptor antagonism potentiates the renoprotection of reninâ€“angiotensin system inhibition in rats with renal mass reduction. Kidney International, 2009, 76, 960-967.	2.6	56
121	Clinical Translation of Mesenchymal Stromal Cell Therapies in Nephrology. Journal of the American Society of Nephrology: JASN, 2018, 29, 362-375.	3.0	55
122	Italy's health performance, 1990â€“2017: findings from the Global Burden of Disease Study 2017. Lancet Public Health, The, 2019, 4, e645-e657.	4.7	54
123	Prevention programmes of progressive renal disease in developing nations (Review Article). Nephrology, 2006, 11, 321-328.	0.7	53
124	Pharmacokinetics of Mycophenolate Sodium and Comparison with the Mofetil Formulation in Stable Kidney Transplant Recipients. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 1147-1155.	2.2	53
125	SEQUENTIAL MONITORING OF URINE-SOLUBLE INTERLEUKIN 2 RECEPTOR AND INTERLEUKIN 6 PREDICTS ACUTE REJECTION OF HUMAN RENAL ALLOGRAFTS BEFORE CLINICAL OR LABORATORY SIGNS OF RENAL DYSFUNCTION. Transplantation, 1997, 63, 1508-1514.	0.5	53
126	Paricalcitol for Secondary Hyperparathyroidism in Renal Transplantation. Journal of the American Society of Nephrology: JASN, 2015, 26, 1205-1214.	3.0	51

#	Article	IF	Citations
127	Kidney failure: aims for the next 10 years and barriers to success. Lancet, The, 2013, 382, 353-362.	6.3	50
128	Atrial Natriuretic Peptide and Prostacyclin Synergistically Mediate Hyperfiltration and Hyperperfusion of Diabetic Rats. Diabetes, 1992, 41, 533-538.	0.3	49
129	Mapping local patterns of childhood overweight and wasting in low- and middle-income countries between 2000 and 2017. Nature Medicine, 2020, 26, 750-759.	15.2	47
130	Strategies for national health care systems in emerging countries: The case of screening and prevention of renal disease progression in Bolivia. Kidney International, 2005, 68, S87-S94.	2.6	46
131	Measuring and Estimating GFR and Treatment Effect in ADPKD Patients: Results and Implications of a Longitudinal Cohort Study. PLoS ONE, 2012, 7, e32533.	1.1	46
132	Effects of MCP-1 Inhibition by Bindarit Therapy in a Rat Model of Polycystic Kidney Disease. Nephron, 2015, 129, 52-61.	0.9	43
133	Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial. PLoS Medicine, 2019, 16, e1002777.	3.9	42
134	Global, Regional, and National Levels of Maternal Mortality, 1990â€“2015: A Systematic Analysis for the Global Burden of Disease Study 2015. Obstetrical and Gynecological Survey, 2017, 72, 11-13.	0.2	41
135	Aging and the kidney. Current Opinion in Nephrology and Hypertension, 2011, 20, 312-317.	1.0	40
136	Mesenchymal stromal cells for tolerance induction in organ transplantation. Human Immunology, 2018, 79, 304-313.	1.2	40
137	Pharmacogenetics of Immunosuppressants: Progress, Pitfalls and Promises. American Journal of Transplantation, 2008, 8, 1374-1383.	2.6	39
138	Angiotensin II Contributes to Diabetic Renal Dysfunction in Rodents and Humans via Notch1/Snail Pathway. American Journal of Pathology, 2013, 183, 119-130.	1.9	39
139	Edema of the Nephrotic Syndrome: The Role of the Atrial Peptide System. American Journal of Kidney Diseases, 1993, 22, 355-366.	2.1	38
140	Ways to Boost Kidney Transplant Viability: A Real Need for the Best Use of Older Donors. American Journal of Transplantation, 2006, 6, 2543-2547.	2.6	37
141	Screening for chronic kidney disease in emerging countries: feasibility and hurdles. Nephrology Dialysis Transplantation, 2009, 24, 1355-1358.	0.4	37
142	Thromboxane A2 receptor blocking abrogates donor-specific unresponsiveness to renal allografts induced by thymic recognition of major histocompatibility allopeptides.. Journal of Experimental Medicine, 1994, 180, 1967-1972.	4.2	36
143	Erythropoietin, but not the correction of anemia alone, protects from chronic kidney allograft injury. Kidney International, 2012, 81, 903-918.	2.6	36
144	Simultaneous determination of everolimus and cyclosporine concentrations by HPLC with ultraviolet detection. Clinica Chimica Acta, 2006, 364, 354-358.	0.5	35

#	Article	IF	Citations
145	Effect of Sirolimus on Disease Progression in Patients with Autosomal Dominant Polycystic Kidney Disease and CKD Stages 3b-4. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 785-794.	2.2	35
146	Cyclosporine induces glomerulosclerosis: Three-dimensional definition of the lesions in a rat model of renal transplant. Kidney International, 1996, 49, 1283-1288.	2.6	34
147	Beneficial effects of calcium channel blockade on acute glomerular hemodynamic changes induced by cyclosporine. American Journal of Kidney Diseases, 1999, 33, 267-275.	2.1	34
148	Trends in cardiovascular diseases burden and vascular risk factors in Italy: The Global Burden of Disease study 1990â€“2017. European Journal of Preventive Cardiology, 2021, 28, 385-396.	0.8	34
149	Ticlopidine prevents renal disease progression in rats with reduced renal mass. Kidney International, 1990, 37, 934-942.	2.6	33
150	Measurement of GFR with a single intravenous injection of nonradioactive iothalamate. Kidney International, 1992, 41, 1081-1084.	2.6	33
151	Peripheral donor leukocytes prolong survival of rat renal allografts. Kidney International, 1999, 56, 1101-1112.	2.6	33
152	Following an Initial Decline, Glomerular Filtration Rate Stabilizes in Heart Transplant Patients on Chronic Cyclosporine. American Journal of Kidney Diseases, 1994, 24, 549-553.	2.1	32
153	Preventing renal and cardiovascular risk by renal function assessment: insights from a cross-sectional study in low-income countries and the USA. BMJ Open, 2012, 2, bmjopen-2012-001357.	0.8	32
154	Combined Treatment with Mycophenolate Mofetil and an Angiotensin II Receptor Antagonist Fully Protects from Chronic Rejection in a Rat Model of Renal Allograft. Journal of the American Society of Nephrology: JASN, 2001, 12, 1937-1946.	3.0	32
155	Community-Based Screening for Chronic Kidney Disease, Hypertension and Diabetes in Dharan. Journal of the Nepal Medical Association, 2013, 52, 205-212.	0.1	32
156	Renal protective effect of angiotensin-converting enzyme inhibition in aging rats. American Journal of Medicine, 1992, 92, S60-S63.	0.6	31
157	Targeted Deletion of Angiotensin II Type 1A Receptor Does not Protect Mice from Progressive Nephropathy of Overload Proteinuria. Journal of the American Society of Nephrology: JASN, 2004, 15, 2666-2674.	3.0	31
158	Neurological symptoms and coma associated with doxorubicin administration during chronic cyclosporin therapy. Lancet, The, 1992, 339, 1421.	6.3	30
159	Toward novel antirejection strategies: In vivo immunosuppressive properties of CTLA4Ig. Kidney International, 1995, 47, 241-246.	2.6	30
160	ACE inhibition limits chronic injury of kidney transplant even with treatment started when lesions are established. Kidney International, 2003, 64, 2253-2261.	2.6	30
161	High-performance liquid chromatography with ultraviolet detection for therapeutic drug monitoring of everolimus. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2005, 816, 99-105.	1.2	30
162	Mesenchymal stromal cells to promote kidney transplantation tolerance. Current Opinion in Organ Transplantation, 2014, 19, 47-53.	0.8	30

#	Article	IF	Citations
163	Diabetes mellitus and chronic kidney disease in the Eastern Mediterranean Region: findings from the Global Burden of Disease 2015 study. International Journal of Public Health, 2018, 63, 177-186.	1.0	30
164	Generic cyclosporine formulations: more open questions than answers. Transplant International, 2005, 18, 371-378.	0.8	29
165	Effects of high dose aleglitazar on renal function in patients with type 2 diabetes. International Journal of Cardiology, 2011, 151, 136-142.	0.8	29
166	Early and late scanning electron microscopy findingsÂin diabetic kidney disease. Scientific Reports, 2018, 8, 4909.	1.6	29
167	Role of enhanced glomerular synthesis of thromboxane A2 in progressive kidney disease. Kidney International, 1990, 38, 447-458.	2.6	28
168	Prevention programs for chronic kidney disease in low-income countries. Internal and Emergency Medicine, 2016, 11, 385-389.	1.0	28
169	ACE and SGLT2 inhibitors: the future for non-diabetic and diabetic proteinuric renal disease. Current Opinion in Pharmacology, 2017, 33, 34-40.	1.7	28
170	Renal Transplantation: Can We Reduce Calcineurin Inhibitor/Stop Steroids? Evidence Based on Protocol Biopsy Findings. Journal of the American Society of Nephrology: JASN, 2003, 14, 755-766.	3.0	27
171	Endothelin Antagonists and Renal Protection. Journal of Cardiovascular Pharmacology, 2000, 35, S75-S78.	0.8	27
172	Endothelin and eicosanoid synthesis in cultured mesangial cells. Kidney International, 1990, 37, 927-933.	2.6	26
173	Abbreviated kinetic profiles in area-under-the-curve monitoring of cyclosporine therapy. Kidney International, 1998, 54, 2146-2150.	2.6	26
174	Chronic kidney disease and neurological disorders: are uraemic toxins the missing piece of the puzzle?. Nephrology Dialysis Transplantation, 2021, 37, ii33-ii44.	0.4	26
175	Assessment of sirolimus concentrations in whole blood by high-performance liquid chromatography with ultraviolet detection. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2002, 774, 187-194.	1.2	25
176	Hyperuricemia in Kidney Transplantation. , 2004, 147, 124-131.		25
177	Thymic Microchimerism Correlates with the Outcome of Tolerance-Inducing Protocols for Solid Organ Transplantation. Journal of the American Society of Nephrology: JASN, 2001, 12, 2815-2826.	3.0	25
178	Preventing end-stage renal disease: the potential impact of screening and intervention in developing countries. Nephrology Dialysis Transplantation, 2003, 18, 858-859.	0.4	24
179	In renal transplantation blood cyclosporine levels soon after surgery act as a major determinant of rejection: Insights from the MY.S.S. Trial. Kidney International, 2004, 65, 1084-1090.	2.6	24
180	Pathophysiology of disease progression in proteinuric nephropathies. Kidney International, 2005, 67, S79-S82.	2.6	24

#	Article	IF	Citations
181	Dual Blockade of the Renin-Angiotensin System: The Ultimate Treatment for Renal Protection?. Journal of the American Society of Nephrology: JASN, 2005, 16, S34-S38.	3.0	24
182	Moderate salt restriction with or without paricalcitol in type 2 diabetes and losartan-resistant macroalbuminuria (PROCEED): a randomised, double-blind, placebo-controlled, crossover trial. Lancet Diabetes and Endocrinology,the, 2018, 6, 27-40.	5.5	24
183	Cyclosporine-induced renal dysfunction in experimental animals and humans. Transplantation Reviews, 1991, 5, 63-80.	1.2	23
184	Research on renal endothelin in proteinuric nephropathies dictates novel strategies to prevent progression. Current Opinion in Nephrology and Hypertension, 2001, 10, 1-6.	1.0	23
185	Mesenchymal stromal cells to control donor-specific memory T cells in solid organ transplantation. Current Opinion in Organ Transplantation, 2015, 20, 79-85.	0.8	23
186	Mapping geographical inequalities in oral rehydration therapy coverage in low-income and middle-income countries, 2000â€“17. The Lancet Global Health, 2020, 8, e1038-e1060.	2.9	23
187	CO-PARTICIPATION OF THROMBOXANE A2 AND LEUKOTRIENE C4 AND D4 IN MEDIATING CYCLOSPORINE-INDUCED ACUTE RENAL FAILURE. Transplantation, 1991, 52, 873-878.	0.5	22
188	Routine renin-angiotensin system blockade in renal transplantation?. Current Opinion in Nephrology and Hypertension, 2002, 11, 1-10.	1.0	22
189	RECOVERY OF BLOOD MONONUCLEAR CELL CALCINEURIN ACTIVITY SEGREGATES TWO POPULATIONS OF RENAL TRANSPLANT PATIENTS WITH DIFFERENT SENSITIVITIES TO CYCLOSPORINE INHIBITION. Transplantation, 1996, 61, 1526-1531.	0.5	22
190	Failure to predict cyclosporine area under the curve using a limited sampling strategy. Kidney International, 1993, 44, 436-439.	2.6	21
191	Preventing end-stage renal disease: The potential impact of screening and intervention in developing countries. Kidney International, 2003, 63, 1948-1950.	2.6	21
192	Acute kidney injury in low-income and middle-income countries: no longer a death sentence. The Lancet Global Health, 2016, 4, e216-e217.	2.9	21
193	Safety of Iohexol Administration to Measure Glomerular Filtration Rate in Different Patient Populations: A 25-Year Experience. Nephron, 2018, 140, 1-8.	0.9	21
194	Acute kidney injury: more awareness needed, globally. Lancet, The, 2015, 386, 1425-1427.	6.3	20
195	Kidney transplant tolerance associated with remote autologous mesenchymal stromal cell administration. Stem Cells Translational Medicine, 2020, 9, 427-432.	1.6	20
196	Third-party bone marrowâ€“derived mesenchymal stromal cell infusion before liver transplantation: A randomized controlled trial. American Journal of Transplantation, 2021, 21, 2795-2809.	2.6	20
197	Assessing Renal Function by GFR Prediction Equations in Kidney Transplantation. American Journal of Transplantation, 2005, 5, 1175-1176.	2.6	19
198	Comparison of the InnofluorÂ® certican assay with HPLC-UV for the determination of everolimus concentrations in heart transplantation. Clinical Biochemistry, 2006, 39, 1152-1159.	0.8	19

#	Article	IF	Citations
199	Intermediate Volume on Computed Tomography Imaging Defines a Fibrotic Compartment that Predicts Glomerular Filtration Rate Decline in Autosomal Dominant Polycystic Kidney Disease Patients. American Journal of Pathology, 2011, 179, 619-627.	1.9	19
200	Mortality landscape in the Global Burden of Diseases, Injuries and Risk Factors Study. European Journal of Internal Medicine, 2014, 25, 1-5.	1.0	19
201	The future of renoprotection. Kidney International, 2005, 68, S95-S101.	2.6	18
202	Aldosterone and progression of kidney disease. Therapeutic Advances in Cardiovascular Disease, 2009, 3, 133-143.	1.0	18
203	Eliminating Treatable Deaths Due to Acute Kidney Injury in Resourceâ€Poor Settings. Seminars in Dialysis, 2015, 28, 193-197.	0.7	18
204	Prevention of progression and remission/regression strategies for chronic renal diseases: Can we do better now than five years ago?. Kidney International, 2005, 68, S21-S24.	2.6	17
205	Non-immune interventions to protect kidney allografts in the long term. Kidney International, 2010, 78, S71-S75.	2.6	17
206	Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial. American Journal of Kidney Diseases, 2019, 74, 338-350.	2.1	17
207	Role of Platelet-Activating Factor in Renal Immune Injury and Proteinuria. American Journal of Nephrology, 1990, 10, 98-104.	1.4	16
208	Angiotensin II receptor antagonists and treatment of hypertension and renal disease. Current Opinion in Nephrology and Hypertension, 1998, 7, 571-578.	1.0	16
209	Sirtuin3 Dysfunction Is the Key Determinant of Skeletal Muscle Insulin Resistance by Angiotensin II. PLoS ONE, 2015, 10, e0127172.	1.1	16
210	Functional implications of decreased renal cortical atrial natriuretic peptide binding in experimental diabetes.. Circulation Research, 1990, 66, 1453-1460.	2.0	15
211	Efficacy and Tolerability of Valsartan Compared with Lisinopril in Patients with Hypertension and Renal Insufficiency. Clinical Drug Investigation, 1997, 14, 252-259.	1.1	15
212	Acquired transplant tolerance. International Journal of Clinical and Laboratory Research, 1997, 27, 165-177.	1.0	15
213	Comparison of different cyclosporine immunoassays to monitor C0 and C2 blood levels from kidney transplant recipients: Not simply overestimation. Clinica Chimica Acta, 2005, 355, 153-164.	0.5	15
214	Determination of Atazanavir in Human Plasma by High-Performance Liquid Chromatography With UV Detection. Journal of Chromatographic Science, 2008, 46, 485-489.	0.7	15
215	Management of chronic kidney disease and its risk factors in eastern Nepal. The Lancet Global Health, 2014, 2, e506-e507.	2.9	15
216	The emergence of regenerative medicine in organ transplantation: 1st European Cell Therapy and Organ Regeneration Section meeting. Transplant International, 2020, 33, 833-840.	0.8	15

#	Article	IF	Citations
217	Losartan in diabetic nephropathy. Expert Review of Cardiovascular Therapy, 2004, 2, 473-483.	0.6	14
218	Cyclosporine Formulation and Kaposiâ€™s Sarcoma after Renal Transplantation. Transplantation, 2005, 80, 743-748.	0.5	14
219	Effect of Timing and Complement Receptor Antagonism on Intragraft Recruitment and Protolerogenic Effects of Mesenchymal Stromal Cells in Murine Kidney Transplantation. Transplantation, 2019, 103, 1121-1130.	0.5	14
220	Albuminuria as a risk factor for mild cognitive impairment and dementiaâ€”what is the evidence?. Nephrology Dialysis Transplantation, 2021, 37, ii55-ii62.	0.4	14
221	Peripheral donor leukocytes prolong survival of rat renal allografts. Kidney International, 1999, 56, 1101.	2.6	14
222	Renal Handling of Sodium in the Nephrotic Syndrome. American Journal of Nephrology, 1993, 13, 413-421.	1.4	13
223	Do mTOR inhibitors still have a future in ADPKD?. Nature Reviews Nephrology, 2010, 6, 696-698.	4.1	13
224	The potential of endothelin antagonism as a therapeutic approach. Expert Opinion on Investigational Drugs, 2004, 13, 1419-1435.	1.9	12
225	Effects of Rosuvastatin on Glomerular Capillary Size-Selectivity Function in Rats with Renal Mass Ablation. American Journal of Nephrology, 2007, 27, 630-638.	1.4	12
226	CTLA4Ig ALONE OR IN COMBINATION WITH LOW-DOSE CYCLOSPORINE FAILS TO REVERSE ACUTE REJECTION OF RENAL ALLOGRAFT IN THE RAT. Transplantation, 1996, 61, 1320-1322.	0.5	12
227	Optimization of cyclosporine therapy in the neoral era: abbreviated AUC, single blood sampling?. Transplantation Proceedings, 2001, 33, 3117-3119.	0.3	11
228	Investigational drugs for diabetic nephropathy. Expert Opinion on Investigational Drugs, 2008, 17, 1487-1500.	1.9	11
229	Prevalence of Hypertension and Diabetes and Coexistence of Chronic Kidney Disease and Cardiovascular Risk in the Population of the Republic of Moldova. International Journal of Hypertension, 2012, 2012, 1-8.	0.5	11
230	Acute Kidney Injury in Poor Countries Should No Longer Be a Death Sentence: The ISN â€˜0 by 25' Project. Annals of Nutrition and Metabolism, 2015, 66, 42-44.	1.0	11
231	Do attributes of persons with chronic kidney disease differ in low-income and middle-income countries compared with high-income countries? Evidence from population-based data in six countries. BMJ Global Health, 2017, 2, e000453.	2.0	11
232	Colchicine allows prolonged survival of highly reactive renal allograft in the rat.. Journal of the American Society of Nephrology: JASN, 1993, 4, 1294-1299.	3.0	11
233	The Lupus Anticoagulant. Experimental Biology and Medicine, 1984, 176, 337-341.	1.1	10
234	Xenotransplantation in the 21st Century. Blood Purification, 2002, 20, 45-54.	0.9	10

#	Article	IF	Citations
235	Inhibition of TGF-Î² expression: A novel role for thiazolidinediones to implement renoprotection in diabetes. Kidney International, 2007, 72, 1419-1421.	2.6	10
236	Pharmacokinetic/Pharmacodynamic Drug Interaction Between Rosiglitazone and Mycophenolate Mofetil in Kidney Transplantation: A Case Report. Transplantation, 2008, 85, 921-922.	0.5	10
237	One or two marginal organs for kidney transplantation?. Transplantation Proceedings, 2002, 34, 3091-3096.	0.3	9
238	Emerging drugs for diabetic nephropathy. Expert Opinion on Emerging Drugs, 2005, 10, 747-771.	1.0	9
239	Abnormalities of Arachidonate Metabolism in Experimental Ciclosporin Nephrotoxicity. American Journal of Nephrology, 1989, 9, 72-77.	1.4	8
240	Abnormalities in arachidonic acid metabolites in nephrotoxic glomerular injury. Toxicology Letters, 1989, 46, 65-75.	0.4	8
241	Morphometrical Analysis of Glomerular Changes Induced by Cyclosporine in the Rat. American Journal of Kidney Diseases, 1991, 17, 537-543.	2.1	8
242	Blood Cyclosporine Level Soon After Kidney Transplantation is a Major Determinant of Rejection: Insights From the Mycophenolate Steroid-Sparing Trial. Transplantation Proceedings, 2005, 37, 2037-2040.	0.3	8
243	Chronic kidney disease in sub-Saharan Africa: a public health priority. The Lancet Global Health, 2014, 2, e124-e125.	2.9	8
244	Pharmacological and clinical profile of valsartan. Drugs of Today, 1998, 34, 973.	0.7	8
245	International Society of Nephrologyâ€™s Perspective on the Emergence of Chronic Kidney Diseases of Unknown/Undetermined Etiology. MEDICC Review, 2014, 16, 75.	0.5	8
246	Limited Sampling Strategies for the Estimation of Sirolimus Daily Exposure in Kidney Transplant Recipients on a Calcineurin Inhibitorâ€"Free Regimen. Journal of Clinical Pharmacology, 2009, 49, 773-781.	1.0	7
247	Renal Graft Function and Low-Dose Cyclosporine Affect Mycophenolic Acid Pharmacokinetics in Kidney Transplantation. Transplantation, 2011, 92, 550-556.	0.5	7
248	Epidemiology of End-Stage Renal Failure. , 2017, , 5-11.		7
249	Mesenchymal Stromal Cells for AKI after Cardiac Surgery. Journal of the American Society of Nephrology: JASN, 2018, 29, 7-9.	3.0	7
250	IMMUNOMODULATION BY INTRATHYMIC INJECTION OF DONOR LEUKOCYTES IN RHESUS MONKEYS1. Transplantation, 2001, 72, 1432-1436.	0.5	7
251	Need for chronic kidney disease prevention programs in disadvantaged populations. Clinical Nephrology, 2015, 83 (2015), 42-48.	0.4	7
252	A comprehensive report of long-term stability data for a range ATMPs: A need to develop guidelines for safe and harmonized stability studies. Cytotherapy, 2022, 24, 544-556.	0.3	7

#	Article	IF	Citations
253	Metabolism of thromboxane B2 in the isolated perfused rat kidney: mass spectrometric identification of urinary products. Lipids and Lipid Metabolism, 1989, 1006, 167-172.	2.6	6
254	Hypertension and kidney function in an adult population of <scp>W</scp>est <scp>B</scp>engal, <scp>I</scp>ndia: Role of body weight, waist circumference, proteinuria and rural area living. Nephrology, 2013, 18, 798-807.	0.7	6
255	Pathogenesis of Preeclampsia. , 1986, , 13-33.		5
256	Therapeutic use of HMG-CoA reductase inhibitors: current practice and future perspectives. Expert Opinion on Therapeutic Patents, 2004, 14, 1553-1566.	2.4	5
257	Kidney prevention recipes for your office practice. Kidney International, 2005, 67, S136-S141.	2.6	5
258	Let's assume that hepatitis C reduces the cardiovascular risk in dialysis patients: Are there practical implications?. Journal of Hepatology, 2006, 44, 837-838.	1.8	5
259	Recent advances in immunosuppression and acquired immune tolerance in renal transplants. American Journal of Physiology - Renal Physiology, 2016, 310, F446-F453.	1.3	5
260	Should We Still Believe in Randomized Controlled Trials in Nephrology?. Nephron, 2017, 136, 281-286.	0.9	5
261	Effects of Tertatolol on Renal Function in the Isolated Perfused Rat Kidney. American Journal of Hypertension, 1989, 2, 223S-227S.	1.0	4
262	Induction of unresponsiveness via intrathymic inoculation. Lancet, The, 1991, 338, 450.	6.3	4
263	Turnour necrosis factor stimulates endothelin-1 gene expression in cultured bovine endothelial cells. Mediators of Inflammation, 1992, 1, 263-266.	1.4	4
264	Section Review Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis: New antirejection drugs. Expert Opinion on Therapeutic Patents, 1996, 6, 871-891.	2.4	4
265	Conflict of interest as seen from a researcherâ€™s perspective. Science and Engineering Ethics, 2002, 8, 337-342.	1.7	4
266	Two-hour post-dose cyclosporine monitoring does not fit all in kidney transplantation. Therapy: Open Access in Clinical Medicine, 2005, 2, 95-105.	0.2	4
267	Drug development: how academia, industry and authorities interact. Nature Reviews Nephrology, 2014, 10, 602-610.	4.1	4
268	Conversion from Brand-Name Neoral to the Generic Ciqorin in Stable Renal Transplant Recipients. Nephron, 2017, 135, 173-180.	0.9	4
269	Pharmacological Induction of Kidney Regeneration. , 2017, , 1025-1037.		4
270	The incessant search for renal biomarkers. Current Opinion in Nephrology and Hypertension, 2019, 28, 195-202.	1.0	4

#	Article	IF	Citations
271	The scientific care for prevention: An overview. Kidney International, 2005, 67, S8-S13.	2.6	3
272	Mycophenolic Acid Formulation Affects Cyclosporine Pharmacokinetics in Stable Kidney Transplant Recipients. Therapeutic Drug Monitoring, 2006, 28, 643-649.	1.0	3
273	Role of thymic- and graft-dependent mechanisms in tolerance induction to rat kidney transplant by donor PBMC infusion. Kidney International, 2007, 71, 1132-1141.	2.6	3
274	Omega-3 Polyunsaturated Fatty Acids Affect Sirolimus Exposure in Kidney Transplant Recipients on Calcineurin Inhibitor-Free Regimen. Transplantation, 2010, 89, 126-127.	0.5	3
275	High serum cholesterol: a missed risk factor for chronic kidney disease mortality. Lancet Diabetes and Endocrinology,the, 2014, 2, 613-614.	5.5	3
276	Nitric oxide and renal perfusion in humans. Journal of Hypertension, 2002, 20, 391-393.	0.3	2
277	A comparison of metrics and performance characteristics of different search strategies for article retrieval for a systematic review of the global epidemiology of kidney and urinary diseases. BMC Medical Research Methodology, 2018, 18, 110.	1.4	2
278	Cyclosporine/tacrolimus (FK-506). , 1998, , 275-300.		2
279	Proteinuria and Tubulotoxicity. , 2019, , 197-214.		2
280	Analysis by fast atom bombardment mass spectrometry of phospholipids from tubuli, glomeruli, and urine of normal rats and rats with acute renal failure. Biochemical Medicine and Metabolic Biology, 1992, 48, 219-226.	0.7	1
281	Pharmacokinetics and renal function after conversion from standard to microemulsion formulation of cyclosporine in stable renal transplant patients. Transplantation Proceedings, 1998, 30, 1654-1655.	0.3	1
282	Optimization of cyclosporine therapy in kidney transplantation. Transplantation Proceedings, 1998, 30, 1673-1676.	0.3	1
283	Calcineurin inhibitors and sirolimus. , 2003, , 403-458.		1
284	Pharmacogenetics and pharmacogenomics of immunosuppressive agents: perspective for individualized therapy. Personalized Medicine, 2004, 1, 53-62.	0.8	1
285	More on Renal Disease Progression: Is Interstitial Inflammation Truly Protective?. Journal of the American Society of Nephrology: JASN, 2007, 18, 1630-1632.	3.0	1
286	Two-hour post-dose cyclosporine monitoring does not fit all in kidney transplantation. Therapy: Open Access in Clinical Medicine, 2005, 2, 95-105.	0.2	1
287	Tacrolimus and ciclosporin microemulsion in renal transplantation. Lancet, The, 2002, 360, 799.	6.3	0
288	Donor hematopoietic cells: central versus peripheral tolerance. Current Opinion in Organ Transplantation, 2004, 9, 284-288.	0.8	0

#	Article	IF	Citations
289	Corrigendum to â€œLetâ€™s assume that hepatitis C reduces the cardiovascular risk in dialysis patients: Are there practical implications?â€•[J Hepatol 44 (2006) 837â€“838]. Journal of Hepatology, 2006, 45, 339.	1.8	0
290	Addressing acute kidney injury in critically ill newborn babies. The Lancet Child and Adolescent Health, 2017, 1, 161-163.	2.7	0
291	Maintenance Immunosuppression in Kidney Transplantation. , 2017, , 259-276.		0
292	Molecular Medicine in Organ Transplantation: How and When?. , 2001, , 317-334.		0
293	Pharmacologic Monitoring of Immunosuppressive Drugs. , 2001, , 43-59.		0
294	Immunomodulation by intrathymic injection of donor leukocytes in rhesus monkeys. Transplantation 2001; 72: 1432.. Transplantation, 2001, 72, 1351-1352.	0.5	0
295	Acute Renal Failure in Kidney Transplant Recipients. , 2009, , 1660-1665.		0
296	Mechanisms and Mediators of Cyclosporine-Induced Renal Vascular Changes. , 1991, , 543-554.		0
297	Acute Renal Failure in Kidney Transplant Recipients. , 2019, , 1279-1285.e3.		0
298	The Bergamo Kidney Transplant Program. Clinical Transplants, 2005, , 85-100.	0.2	0